RNS Number : 2758U MaxCyte, Inc. 01 December 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 1 December 2021 : MaxCyte (LSE: MXCT, MXCN), a leading commercial cell - engineering company focused on providing enabling platform technologies to
RNS Number : 2493T MaxCyte, Inc. 23 November 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Purchase of Common Stock - PDMR dealing Gaithersburg, Maryland , November 23, 2021 - M axCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused
RNS Number : 7413S MaxCyte, Inc. 17 November 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options, PDMR dealing and Total Voting Rights Gaithersburg, Maryland , November 17, 2021 - M axCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial
GAITHERSBURG, Md., Nov. 12, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,
RNS Number : 0207S MaxCyte, Inc. 11 November 2021 MaxCyte Reports Third Quarter Financial Results GAITHERSBURG, MD , November 11, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to
GAITHERSBURG, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,
GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN) is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,
RNS Number : 2161R MaxCyte, Inc. 03 November 2021 MaxCyte Board Member Richard Douglas , PhD, Appointed Independent Chairman of the Board GAITHERSBURG, MD , Nov. 3, 2021 - MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT, MXCN) is a leading commercial cell-engineering company focused on
GAITHERSBURG, Md., Oct. 29, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,
RNS Number : 7940Q MaxCyte, Inc. 29 October 2021 Result of AGM GAITHERSBURG, MD , October 29, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research
